Gilead, AstraZeneca and Roche favor pipeline deals over big buyouts
Big pharma spent the week on discovery partnerships and early candidates in obesity and cancer rather than major acquisitions, Stocktwits reports.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
According to Stocktwits, Gilead Sciences, AstraZeneca, Roche and Pfizer spent the week locking in access to discovery platforms and experimental candidates aimed at unmet biological needs, rather than buying rival companies or approved medicines. Obesity and cancer were the main focal points.
On Wednesday Gilead teamed up with Vir Biotechnology to find and develop three drugs for solid tumors. Vir stands to collect $90 million at signing, made up of $65 million in cash and a $25 million stake bought at a premium, plus up to $45 million in early preclinical milestones and as much as $1.74 billion in later stage payments, along with tiered royalties. AstraZeneca signed with insitro, a privately held AI firm, on metabolic liver disease (MASH) and cardiomyopathies. insitro gets $40 million upfront and up to roughly $1.46 billion in milestones, with single-digit royalties.
Roche obtained exclusive worldwide rights to an investigational compound from Rona Therapeutics that targets a protein found mainly in fat tissue. Rona may receive up to $100 million upfront and near-term payments, and up to $1.06 billion more in milestones. Separately, Zealand Pharma agreed with Generate Biomedicines on multispecific protein drugs for obesity. Generate gets $30 million upfront, up to $35 million in early preclinical milestones and almost $1.2 billion of total potential milestones. Pfizer partnered with Enodia Therapeutics in a deal with potential value above $500 million.
why it matters
For the sector, these agreements show large drugmakers preferring access to early-stage obesity and oncology programs over takeovers of rivals. Stocktwits notes that retail sentiment on the SPDR S&P Biotech ETF (XBI) shifted from bullish to neutral over the past day. The fund has slipped about 4% in the past week after a mid-August peak near $170, though it is up 22.5% year-to-date.
market impact
Biotech: large licensing deals support sector interest and the XBI ETF
tags
instruments
sources
- Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts — stocktwits.com, 16 October 2026 at 23:57 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗